The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-0485
Full Text
Open PDFAbstract
Available in full text
Date
July 30, 2015
Authors
Publisher
American Association for Cancer Research (AACR)